Pharmaceutical composition containing prasugrel and carvedilol, and purpose thereof

A technology of carvedilol phosphate and its composition, which is applied in the field of medicine, can solve the problems of unsustainable effect of prasugrel-like drugs, poor therapeutic effect, and single symptoms, and achieve the reduction of prasugrel resistance, Reduce the incidence of atherosclerosis and cardiovascular and cerebrovascular thrombosis events, and reduce the effect of toxic and side effects

Active Publication Date: 2015-05-13
LUNAN PHARMA GROUP CORPORATION
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] In order to overcome the shortcomings of the prior art that the existing drugs for cardiovascular and cerebrovascular diseases have single symptoms and poor therapeutic effect, prasugrel-like drugs have resistance phenomenon in the human body, and the effect of single drug administration cannot last, the present invention provides a new Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing prasugrel and carvedilol, and purpose thereof
  • Pharmaceutical composition containing prasugrel and carvedilol, and purpose thereof
  • Pharmaceutical composition containing prasugrel and carvedilol, and purpose thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1 Compound Prasugrel Carvedilol Tablets

[0028]

[0029] Preparation process: weigh the prescription amount of carvedilol, prasugrel, starch, dextrin and low-substituted hydroxypropyl cellulose and mix them evenly. Another suitable amount of 60% ethanol is added to the mixed powder, and the soft material is made after uniform mixing, which is granulated through a 16-mesh sieve and dried below 60°C. After drying, use an 18-mesh sieve to sizing, sieve out the fine powder in the dry granules, mix them with the sieved magnesium stearate, and then mix them with the dry granules evenly, press the tablet, and get it.

Embodiment 2

[0030] Example 2 Compound Prasugrel Carvedilol Tablets

[0031]

[0032] Preparation process: Weigh the prescribed amount of carvedilol, prasugrel, microcrystalline cellulose and hydroxypropyl cellulose and mix them evenly. Another suitable amount of 8% starch slurry solution is added to the mixed powder, mixed evenly to make soft material, granulated through a 16-mesh sieve, and dried below 60°C. After drying, use an 18-mesh sieve to sizing, sieve out the fine powder in the dry granules, mix them with the sieved magnesium stearate, and then mix them with the dry granules evenly, press the tablet, and get it.

Embodiment 3

[0033] Example 3 Compound Prasugrel Carvedilol Tablets

[0034]

[0035] Preparation process: weigh the prescription amount of carvedilol, prasugrel, starch, dextrin and low-substituted hydroxypropyl cellulose and mix them evenly. Another suitable amount of 60% ethanol is added to the mixed powder, and the soft material is made after uniform mixing, which is granulated through a 16-mesh sieve and dried below 60°C. After drying, use an 18-mesh sieve to sizing, sieve out the fine powder in the dry granules, mix them with the sieved magnesium stearate, and then mix them with the dry granules evenly, press the tablet, and get it.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicines, and discloses a pharmaceutical composition used for treating cardiovascular and cerebrovascular diseases. According to the pharmaceutical composition provided by the invention, prasugrel or a pharmaceutically acceptable salt thereof, and carvedilol or a pharmaceutically acceptable salt thereof are adopted as pharmaceutically active ingredients. Carvedilol or the pharmaceutically acceptable salt thereof is calculated according to carvedilol, and prasugrel or the pharmaceutically acceptable salt thereof is calculated according to prasugrel. In the pharmaceutical composition, the weight ratio of carvedilol to prasugrel is 1:0.01-100, and preferably 1:0.2-20. When the pharmaceutical composition is applied in treating cardiovascular and cerebrovascular diseases, the effect is comprehensive, the toxic and side effects are low, and patient compliance can be improved. Therefore, the pharmaceutical composition has good medical application prospect.

Description

Technical field [0001] The invention belongs to the field of medicine, and specifically relates to a pharmaceutical composition containing prasugrel and carvedilol and uses thereof. Background technique [0002] Cardio-cerebrovascular diseases include coronary heart disease, angina pectoris, myocardial infarction, congestive pulmonary heart disease, ischemic encephalopathy, cerebral thrombosis, hypertension, hyperlipidemia, etc. The main cause of these diseases is arteriosclerosis that causes stenosis of the lumen and blockage of the ducts, which leads to insufficient blood supply to the heart and brain, causing symptoms such as head heavy, dizziness, headache, chest tightness, and severe cases can lead to stroke and myocardial infarction. After heart and brain ischemia, it affects energy metabolism, secondary to lactic acid accumulation, calcium overload, free radical damage and other changes. Reversing or improving these changes with multiple targets and improving the overall ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4365A61K31/403A61P9/10A61P9/12A61P3/06A61P7/02A61P9/04A61P9/00
Inventor 赵志全杨鉴冯芹
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap